Cargando…
Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies
Epidermal growth factor receptor (EGFR) inhibitors are widely used to treat various types of cancers such as non-small cell lung cancer, head and neck cancer, breast cancer, pancreatic cancer. Adverse reactions such as skin toxicity, interstitial lung disease, hepatotoxicity, ocular toxicity, hypoma...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866822/ https://www.ncbi.nlm.nih.gov/pubmed/35223483 http://dx.doi.org/10.3389/fonc.2022.804212 |
_version_ | 1784655915672141824 |
---|---|
author | Li, Yanping Fu, Ruoqiu Jiang, Tingting Duan, Dongyu Wu, Yuanlin Li, Chen Li, Ziwei Ni, Rui Li, Li Liu, Yao |
author_facet | Li, Yanping Fu, Ruoqiu Jiang, Tingting Duan, Dongyu Wu, Yuanlin Li, Chen Li, Ziwei Ni, Rui Li, Li Liu, Yao |
author_sort | Li, Yanping |
collection | PubMed |
description | Epidermal growth factor receptor (EGFR) inhibitors are widely used to treat various types of cancers such as non-small cell lung cancer, head and neck cancer, breast cancer, pancreatic cancer. Adverse reactions such as skin toxicity, interstitial lung disease, hepatotoxicity, ocular toxicity, hypomagnesemia, stomatitis, and diarrhea may occur during treatment. Because the EGFR signaling pathway is important for maintaining normal physiological skin function. Adverse skin reactions occurred in up to 90% of cancer patients treated with EGFR inhibitors, including common skin toxicities (such as papulopustular exanthemas, paronychia, hair changes) and rare fatal skin toxicities (e.g., Stevens–Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis). This has led to the dose reduction or discontinuation of EGFR inhibitors in the treatment of cancer. Recently, progress has been made about research on the skin toxicity of EGFR inhibitors. Here, we summarize the mechanism of skin toxicity caused by EGFR inhibitors, measures to prevent severe fatal skin toxicity, and provide reference for medical staff how to give care and treatment after adverse skin reactions. |
format | Online Article Text |
id | pubmed-8866822 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88668222022-02-25 Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies Li, Yanping Fu, Ruoqiu Jiang, Tingting Duan, Dongyu Wu, Yuanlin Li, Chen Li, Ziwei Ni, Rui Li, Li Liu, Yao Front Oncol Oncology Epidermal growth factor receptor (EGFR) inhibitors are widely used to treat various types of cancers such as non-small cell lung cancer, head and neck cancer, breast cancer, pancreatic cancer. Adverse reactions such as skin toxicity, interstitial lung disease, hepatotoxicity, ocular toxicity, hypomagnesemia, stomatitis, and diarrhea may occur during treatment. Because the EGFR signaling pathway is important for maintaining normal physiological skin function. Adverse skin reactions occurred in up to 90% of cancer patients treated with EGFR inhibitors, including common skin toxicities (such as papulopustular exanthemas, paronychia, hair changes) and rare fatal skin toxicities (e.g., Stevens–Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis). This has led to the dose reduction or discontinuation of EGFR inhibitors in the treatment of cancer. Recently, progress has been made about research on the skin toxicity of EGFR inhibitors. Here, we summarize the mechanism of skin toxicity caused by EGFR inhibitors, measures to prevent severe fatal skin toxicity, and provide reference for medical staff how to give care and treatment after adverse skin reactions. Frontiers Media S.A. 2022-02-10 /pmc/articles/PMC8866822/ /pubmed/35223483 http://dx.doi.org/10.3389/fonc.2022.804212 Text en Copyright © 2022 Li, Fu, Jiang, Duan, Wu, Li, Li, Ni, Li and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Li, Yanping Fu, Ruoqiu Jiang, Tingting Duan, Dongyu Wu, Yuanlin Li, Chen Li, Ziwei Ni, Rui Li, Li Liu, Yao Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies |
title | Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies |
title_full | Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies |
title_fullStr | Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies |
title_full_unstemmed | Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies |
title_short | Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies |
title_sort | mechanism of lethal skin toxicities induced by epidermal growth factor receptor inhibitors and related treatment strategies |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866822/ https://www.ncbi.nlm.nih.gov/pubmed/35223483 http://dx.doi.org/10.3389/fonc.2022.804212 |
work_keys_str_mv | AT liyanping mechanismoflethalskintoxicitiesinducedbyepidermalgrowthfactorreceptorinhibitorsandrelatedtreatmentstrategies AT furuoqiu mechanismoflethalskintoxicitiesinducedbyepidermalgrowthfactorreceptorinhibitorsandrelatedtreatmentstrategies AT jiangtingting mechanismoflethalskintoxicitiesinducedbyepidermalgrowthfactorreceptorinhibitorsandrelatedtreatmentstrategies AT duandongyu mechanismoflethalskintoxicitiesinducedbyepidermalgrowthfactorreceptorinhibitorsandrelatedtreatmentstrategies AT wuyuanlin mechanismoflethalskintoxicitiesinducedbyepidermalgrowthfactorreceptorinhibitorsandrelatedtreatmentstrategies AT lichen mechanismoflethalskintoxicitiesinducedbyepidermalgrowthfactorreceptorinhibitorsandrelatedtreatmentstrategies AT liziwei mechanismoflethalskintoxicitiesinducedbyepidermalgrowthfactorreceptorinhibitorsandrelatedtreatmentstrategies AT nirui mechanismoflethalskintoxicitiesinducedbyepidermalgrowthfactorreceptorinhibitorsandrelatedtreatmentstrategies AT lili mechanismoflethalskintoxicitiesinducedbyepidermalgrowthfactorreceptorinhibitorsandrelatedtreatmentstrategies AT liuyao mechanismoflethalskintoxicitiesinducedbyepidermalgrowthfactorreceptorinhibitorsandrelatedtreatmentstrategies |